BRD4 and cancer: More than a dozen BRD4 BD1 and BD2 bromodomain inhibitors, including ABBV-075, AZD5153, BAY 1238097, BMS-986158, BMS-986378, CC-90010, CPI-0610, FT-1101, GSK525762 (Molibresib), INCB054329, INCB057643, ODM-207, OTX015 and PLX51107 have been or are currently in clinical trials in patients with cancer from various organ origins.